CN107929268A - A kind of transdermal patch of the medicine containing proton pump inhibitor and preparation method thereof - Google Patents
A kind of transdermal patch of the medicine containing proton pump inhibitor and preparation method thereof Download PDFInfo
- Publication number
- CN107929268A CN107929268A CN201711372090.7A CN201711372090A CN107929268A CN 107929268 A CN107929268 A CN 107929268A CN 201711372090 A CN201711372090 A CN 201711372090A CN 107929268 A CN107929268 A CN 107929268A
- Authority
- CN
- China
- Prior art keywords
- transdermal patch
- pump inhibitor
- proton pump
- medicine containing
- containing proton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
Abstract
The present invention relates to a kind of transdermal patch of medicine containing proton pump inhibitor, it is characterised in that the transdermal patch is mainly by back sheet, drug storehouse layer and anti-stick layer composition；The drug storehouse layer is mainly made of the component of following weight percentage：Active ingredient 0.1-40%, Drug Storage matrix 20-90%, stabilizer 1-5%, percutaneous absorption fortifier 1-30%, dispersant 0-20%.Invention transdermal patch can effectively realize the sustained transdermal of medicine long period, maintain constant blood concentration, and preparation percutaneous absorption rate is fast, and Transdermal absorption amount is high, have the characteristics that stable, efficient, medication is safer.
Description
Technical field
The invention belongs to technical field of medicine, and in particular to a kind of transdermal patch of medicine containing proton pump inhibitor and
Its preparation method.
Background technology
Reflux esophagitis（RE）It is one of most common enterogastric diseases, it is mainly anti-by Stomach duodenum content
Flow into esophagitis venereal disease caused by oesophagus to become, Endoscopic Features are the breakage of Esophageal Mucosa, i.e. oesophagus erosion and (or) oesophagus
Ulcer.Reflux esophagitis can betide the crowd at any age, and adult's incidence increases and raises with the age.It is Hesperian
Incidence is high, and Asia incidence is low.This geographic difference may be related with h and E factor.But recent two decades
The incidence in the whole world is all on the rise.Middle-aged and elderly people, obesity, smoking, drink and stress is reflux esophagitis greatly
Group of people at high risk.Disease morbidity is anxious, and state of an illness length, there is bleeding perforated ulcer risk when serious, the serious health for damaging the people.
Esomeprazole, is the S configurational isomers of Omeprazole, by suppress the H+/K+-ATP enzymes of parietal cell come
Gastric acid secretion is reduced, prevents the formation of hydrochloric acid in gastric juice.It is clinically used for gastroesophageal reflux disease, erosive reflux esophagitis is controlled
Treat, the esophagitis patient cured prevents the long term maintenance therapy of recurrence, the symptom control of gastroesophageal reflux disease, with fitting
When antimicrobial therapy drug combination eradicate helicobacter pylori, and heal and infect relevant duodenal ulcer with helicobacter pylorus,
Prevent and the relevant recurrent peptic ulcer of helicobacter pylori.Esomeprazole clinically use its salt as active ingredient into
Row pharmaceutical manufacturing, such as esomeprazole magnesium, esomeprazole sodium etc..Esomeprazole salt is extremely unstable, acid condition
Under easily degrade；Racemization easily occurs at normal temperatures for aqueous solution.Therefore, which is usually made enteric coated preparations and supplied by clinical application
Gastrointestinal administration, or lyophilized formulations are made and are total to parenteral administration.
Transdermal drug delivery system or transdermal formulation, refer to be administered in skin surface, make medicine with constant rate of speed（It is or close
Constant rate of speed）Body circulation is entered by skin and produces whole body or the novel form of local therapeutic effects.Its advantage is embodied in：Medicine is inhaled
Receipts influence from the factor such as pH, food, transhipment time in alimentary canal；Avoid liver first-pass effect；Overcome because absorbing too fast generation
Adverse reaction caused by blood concentration is excessive；Sustainable control injection speed, flexibly administration etc..Cutaneous penetration is that new development rises
The novel Drug Delivery Systems come, in view of the continuous development of its more humane drug treatment feature and percutaneous technique, can have more
Wide prospect.
Transdermal patch is made in esomeprazole salt, medicine is by being absorbed into body fluid circulatory after cutaneous penetration, effectively
Avoid influences of the intestines and stomach pH to medicine stability；Increase medicine stability by adjusting drug storehouse layer ratio of adjuvant；External application is saturating
Leather agent convenient drug administration, can discontinue medication immediately when there is toxicity, security higher；Compare injection, preparation capable of permeating skin
Special administration place and mode is not required, therefore patient's compliance is high.
The content of the invention
Present invention aims to overcome that prior art defect, there is provided a kind of transdermal patch of medicine containing proton pump inhibitor,
The transdermal patch carries out cutaneous penetration by proton pump inhibitor, and medicine enters blood circulation inside body, reaches therapeutic dose, its energy
Enough sustained transdermals for effectively realizing the medicine long period, maintain constant blood concentration, and preparation percutaneous absorption rate is fast, transdermal
Uptake is high, has the advantages that convenient drug administration, security higher.
Present invention also offers the preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of transdermal patch of medicine containing proton pump inhibitor, the transdermal patch is mainly by back sheet, drug storehouse layer and anti-stick layer group
Into；The drug storehouse layer is mainly made of the component of following weight percentage：0.1-40%, Drug Storage matrix 20-90%, stabilizer
1-5%, percutaneous absorption fortifier 1-30%, dispersant 0-20%.
Back sheet（Supporting layer）Basic demand be：With enough intensity with the globality of support system, have at the same time
Enough pliabilitys are in close contact system and the shape of body agents area.Specifically, the material bag of the back sheet
Include but be not limited to non-woven fabrics, woven cloth or non-woven fabrics and the composite material of woven cloth.Non-woven fabrics includes but not limited to polyolefin tree
Lipid materials such as polyethylene, polypropylene etc.；Polyester resin material class such as polyethylene terephthalate, poly terephthalic acid
Glycol ester, polyethylene naphthalate etc..Woven cloth includes but not limited to cotton, artificial silk, polyacrylate, polyester etc.
Or their compound.
Anti-stick layer is to be covered in Drug Storage layer surface to be used to protect the drug storehouse layer containing proton pump inhibitor active medicine.When
When proton pump inhibitor transdermal drug delivery system is applied to human body, anti-stick layer can be thereafter easily released, will not adhesive tape walk Drug Storage
Raw material composition in layer.The material of anti-stick layer include through the processed polyethylene plated film of silica gel single side without wooden paper, polyester film,
Polyethylene film, polypropylene screen etc..The size of anti-stick layer is identical with back sheet.
Drug storehouse layer is the core of the transdermal patch of the medicine containing proton pump inhibitor.Drug storehouse layer provided by the present invention forms structure
Into the key of the cutaneous penetration technology of system.The drug storehouse layer composition of the present invention provide the sustained transdermal of proton pump inhibitor to
Medicine ability.Drug storehouse layer includes but not limited to active ingredient, Drug Storage matrix, stabilizer, percutaneous absorption fortifier, dispersant etc..
Specifically, active ingredient of the present invention is proton pump inhibitor, proton pump inhibitor mainly includes Chinese mugwort department Aomei
Draw azoles salt.
Specifically, Drug Storage matrix of the present invention is pressure sensitive adhesive.Pressure sensitive adhesive refers to work as to be applied to system
With adhesive during pressure and adhering skin.Pressure sensitive adhesive includes but not limited to natural rubber, polyisobutene, butylene rubber
Glue, polyprene, silicon rubber, silicone copolymer, polyacrylate, methacrylate, acrylic acid/methacrylate copolymers
Thing, ethylene/vinyl acetate, ethene/acrylic ester copolymer, styrol copolymer or polyurethane etc.；It is preferred that propylene
Acid esters pressure sensitive adhesive, available model can be but not limited to acrylate pressure-sensitive adhesive 87-2287, acrylate pressure-sensitive adhesive 87-
4098th, acrylate pressure-sensitive adhesive 87-2852, acrylate pressure-sensitive adhesive MG-0607 etc..
Stabilizer in the present invention is the guarantee medicine material that chemical property is stablized in drug storehouse layer.It is specifically, of the invention
The stabilizer is mainly alkaline matter or the material that can provide alkaline environment, including but not limited to alkaline, inorganic salts, such as hydrogen
Sodium oxide molybdena, sodium carbonate, potassium hydroxide etc., preferably sodium hydroxide.
Percutaneous absorption fortifier in the present invention is for strengthening the Transdermal absorption ability to certain drug.Used in the present invention
Include, but are not limited in the percutaneous absorption fortifier of enhancing proton pump inhibitor Transdermal absorption：
1）Aliphatic alcohols compound, such as saturation or unsaturated fatty alcohol of the carbon number between 12-22, such as oleyl alcohol, laruyl alcohol；
2）Fatty acid ester compound, such as isopropyl myristate, diisopropyl adipate, isopropyl palmitate；
3）Alcamine compound, such as triethanolamine, diisopropanolamine (DIPA)；
4）Polyol alkyl ether class compound, such as glycerine, ethylene glycol, propane diols, 1,3-BDO, diglycerol, diethylene glycol (DEG), poly- second
Glycol, sorbitan, D-sorbite, Isosorbide Mononitrate, methyl glucoside, oligosaccharides etc.；
5）The fatty glyceride of glyceride type compound, such as carbon number between 6-18；
6）Aminated compounds, such as urea, dimethylaminoethyl；
7）Phosphorus ester type compound, including lecithin, Fabaceous Lecithin or phosphatidyl glycerol etc.；
8）Terpene compound, such as cineole, limonene or flores aurantii tree alcohol etc.；
Wherein, preferred alcamine compound, polyol alkyl ether class compound, aminated compounds.
Specifically, the dispersant is selected from propane diols, glycerine, n-octyl alcohol, n-dodecanol, polyethylene glycol 200, poly- second two
Alcohol 400 or Macrogol 600.It is preferred that propane diols, glycerine, polyethylene glycol 200 or polyethylene glycol 400.
A kind of preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor, it includes the following steps：
1）Active ingredient is dissolved in etoh solvent, ethyl acetate or acetone, acquisition contains drug solns；
2）Stabilizer and percutaneous absorption fortifier are added in Drug Storage matrix, is then added in dispersant, when adjusting 25 DEG C of glue
Viscosity to 350-2000cp, with the speed of 2000-10000rpm stir 0 .5-2 it is small when；
3）By step 2）Products therefrom adds step 1）In products therefrom, 10-30mi are stirred with the speed of 500-1000rpm；
4）By step 3）Products therefrom is coated on back sheet, and coating thickness is 0.10-0.5mm, 60-90 DEG C of dryings 0.5-1
Hour, then cover anti-stick layer, that is, obtain transdermal patch.
The present invention transdermal patch in use, can be attached on the intact skin of human body, 1 tablet once, with area 5-
50cm2To be suitable.It is raw materials used in the present invention directly to buy ordinary commercial products.
Compared to the prior art, beneficial effects of the present invention：
The present invention provides a kind of transdermal patch of medicine containing proton pump inhibitor, which can not only be continued above 24
Hour insoluble drug release and transdermal, medicine is released into human body by skin in the delivery system plays drug effect, while can
Stable blood concentration is maintained, reduction takes frequency, increases the compliance and compliance of patient；Transdermal route avoids medicine at the same time
Thing is taken orally through intestines and stomach, and reduce medicine is influenced and the first pass effect of liver by gastroenteric environment, is had the bioavilability of higher, is being cured
Application is treated above to have a clear superiority.Transdermal patch of the present invention can effectively realize the sustained transdermal of medicine long period, remain permanent
Fixed blood concentration, and preparation percutaneous absorption rate is fast, Transdermal absorption amount is high, has the characteristics that stable, efficient.
Brief description of the drawings
Fig. 1 is the accumulation transport through skin speed that embodiment 1 prepares gained transdermal patch product；
Fig. 2 is the accumulation transport through skin speed that embodiment 2 prepares gained transdermal patch product；
Fig. 3 is the accumulation transport through skin speed that embodiment 3 prepares gained transdermal patch product；
Fig. 4 is the accumulation transport through skin speed that embodiment 4 prepares gained transdermal patch product.
Embodiment
Technical scheme is further discussed in detail with reference to embodiments, but protection scope of the present invention
It is not limited thereto.
Embodiment 1
A kind of transdermal patch of medicine containing proton pump inhibitor, the transdermal patch is from top to bottom by back sheet, drug storehouse layer and anti-stick
Layer composition；The material of the back sheet is non-woven fabrics；The anti-stick layer is polyethylene film.The each component weight of the drug storehouse layer
Percentage is as shown in the table.
The preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor, it includes the following steps：
1）During active ingredient esomeprazole sodium is dissolved in, acquisition contains drug solns；
2）Stabilizer sodium hydroxide and the poly- second of percutaneous absorption fortifier are added in Drug Storage matrix propylene acid esters pressure sensitive adhesive 87-2287
Glycol 400, then adds in dispersant propane diols, and viscosity when adjusting 25 DEG C of glue is stirred to 1500cp with the speed of 6000rpm
Mix 2 it is small when；
3）By step 2）Products therefrom adds step 1）In products therefrom, 20mi is stirred with the speed of 1000rpm；
4）By step 3）Products therefrom is coated on back sheet, coating thickness 0.25mm, and 90 DEG C of dryings 0.5 are molten to volatilize when small
Agent ethanol, then cover anti-stick layer, that is, obtain transdermal patch product.
Patch transdermal experiment：
It is measured using Franz diffusion cells, by the use of nude mice intact skin as skin is passed through, is made with 30% PEG400 aqueous solutions
To receive medium, reception tank rotating speed is set to 200rpm, 32 ± 0.5 DEG C of temperature, and the transdermal patch product that embodiment 1 is prepared pastes
In skin keratin aspect, dermis of skin is contacted with receiving medium-tight, and spot sampling measure, per sub-sampling 0.5ml, sampling finishes
Supply 0.5ml in Franz diffusion cells immediately afterwards and receive medium.Content determination determination sample concentration is used after sample treatment.
The accumulation transport through skin speed that embodiment 1 prepares gained esomeprazole sodium transdermal patch product is shown in Fig. 1.In figure
It can be seen that：The esomeprazole sodium transdermal patch product is good through the release of nude mice skin, and 48h release amount of medicine is
95.5%。
Embodiment 2
A kind of transdermal patch of medicine containing proton pump inhibitor, the transdermal patch is from top to bottom by back sheet, drug storehouse layer and anti-stick
Layer composition；The material of the back sheet is woven cloth；The anti-stick layer is polypropylene screen.The each component weight of the drug storehouse layer
Percentage is as shown in the table.
The preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor is with reference to embodiment 1.Using foregoing same
Method carries out percutaneous penetration, and experimental result is shown in Fig. 2.As shown in Figure 2：Esomeprazole sodium prepared by embodiment 2 is transdermal
Patch is good through the release of nude mice skin, and 48h release amount of medicine is 100.0%.
Embodiment 3
A kind of transdermal patch of medicine containing proton pump inhibitor, the transdermal patch is from top to bottom by back sheet, drug storehouse layer and anti-stick
Layer composition；The each component percentage by weight of the drug storehouse layer is as shown in the table；Other reference embodiments 1.
The preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor is with reference to embodiment 1.Using foregoing same
Method carries out percutaneous penetration, and experimental result is shown in Fig. 3.As shown in Figure 3：Esomeprazole sodium prepared by embodiment 3 is transdermal
Patch is good through the release of nude mice skin, and 48h release amount of medicine is 94.6%.
Embodiment 4
A kind of transdermal patch of medicine containing proton pump inhibitor, the transdermal patch is from top to bottom by back sheet, drug storehouse layer and anti-stick
Layer composition；The each component percentage by weight of the drug storehouse layer is as shown in the table；Other reference embodiments 1.
The preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor is with reference to embodiment 1.Using foregoing same
Method carries out percutaneous penetration, and experimental result is shown in Fig. 4.As shown in Figure 4：Esomeprazole sodium prepared by embodiment 4 is transdermal
Patch is good through the release of nude mice skin, and 48h release amount of medicine is 96.8%
Embodiment 5-7
A kind of transdermal patch of medicine containing proton pump inhibitor, the transdermal patch is from top to bottom by back sheet, drug storehouse layer and anti-stick
Layer composition；The each component percentage by weight of the drug storehouse layer is as shown in the table；Other reference embodiments 1.
The preparation method of the transdermal patch of the above-mentioned medicine containing proton pump inhibitor is with reference to embodiment 1.Using foregoing same
Method carries out percutaneous penetration, and experimental result is understood：Esomeprazole sodium transdermal patch prepared by embodiment 5-7 is through naked
The release of mouse skin is good, suitable with 4 effect of embodiment.
Claims (10)
1. the transdermal patch of a kind of medicine containing proton pump inhibitor, it is characterised in that the transdermal patch is mainly by back sheet, Drug Storage
Layer and anti-stick layer composition；The drug storehouse layer is mainly made of the component of following weight percentage：Active ingredient 0.1-40%, Drug Storage
Matrix 20-90%, stabilizer 1-5%, percutaneous absorption fortifier 1-30%, dispersant 0-20%.
2. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 1, it is characterised in that the material of the back sheet
Composite material including non-woven fabrics, woven cloth or non-woven fabrics and woven cloth.
3. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 1, it is characterised in that the material of the anti-stick layer
Including through the processed polyethylene plated film of silica gel single side without wooden paper, polyester film, polyethylene film or polypropylene screen；Anti-stick layer
Size is identical with back sheet.
4. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 1, it is characterised in that the active ingredient is matter
Sub- pump inhibitor；The Drug Storage matrix is pressure sensitive adhesive；The stabilizer is alkaline, inorganic salts.
5. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 4, it is characterised in that the proton pump inhibitor
For esomeprazole salt.
6. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 4, it is characterised in that the pressure-sensitive adhesive
Agent includes natural rubber, polyisobutene, butene rubber, polyprene, silicon rubber, silicone copolymer, polyacrylate, methyl-prop
Olefin(e) acid ester, acrylic acid/methacrylate copolymers, ethylene/vinyl acetate, ethene/acrylic ester copolymer, benzene
Ethylene copolymer or polyurethane.
7. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 4, it is characterised in that the alkaline, inorganic salts are
Sodium hydroxide, sodium carbonate or potassium hydroxide.
8. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 1, it is characterised in that the Transdermal absorption enhancing
Agent includes aliphatic alcohols compound, fatty acid ester compound, alcamine compound, polyol alkyl ether class compound, glycerine
Ester type compound, aminated compounds, phosphide class or terpene compound.
9. the transdermal patch of the medicine containing proton pump inhibitor as claimed in claim 1, it is characterised in that the dispersant is selected from third
Glycol, glycerine, n-octyl alcohol, n-dodecanol, polyethylene glycol 200, polyethylene glycol 400 or Macrogol 600.
10. the preparation method of the transdermal patch of the medicine containing proton pump inhibitor described in claim 1, it is characterised in that including such as
Lower step：
1）Active ingredient is dissolved in etoh solvent, ethyl acetate or acetone, acquisition contains drug solns；
2）Stabilizer and percutaneous absorption fortifier are added in Drug Storage matrix, is then added in dispersant, gluing when adjusting 25 DEG C
Spend to 350-2000cp, when small with 0 .5-2 of speed stirring of 2000-10000rpm；
3）By step 2）Products therefrom adds step 1）In products therefrom, 10-30mi are stirred with the speed of 500-1000rpm；
4）By step 3）Products therefrom is coated on back sheet, and coating thickness is 0.10-0.5mm, 60-90 DEG C of dryings 0.5-1
Hour, then cover anti-stick layer, that is, obtain transdermal patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711372090.7A CN107929268A (en) | 2017-12-19 | 2017-12-19 | A kind of transdermal patch of the medicine containing proton pump inhibitor and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711372090.7A CN107929268A (en) | 2017-12-19 | 2017-12-19 | A kind of transdermal patch of the medicine containing proton pump inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107929268A true CN107929268A (en) | 2018-04-20 |
Family
ID=61940753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711372090.7A Pending CN107929268A (en) | 2017-12-19 | 2017-12-19 | A kind of transdermal patch of the medicine containing proton pump inhibitor and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107929268A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024037545A1 (en) * | 2022-08-17 | 2024-02-22 | 宜昌人福药业有限责任公司 | Dexmedetomidine transdermal composition, transdermal patch, and method for preparing transdermal patch and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005097083A2 (en) * | 2004-03-30 | 2005-10-20 | Dermatrends,Inc. | Transdermal administration of proton pump inhibitors |
| EP2214643B1 (en) * | 2007-11-02 | 2014-04-02 | Acrux DDS Pty Ltd | Transdermal delivery system for hormones and steroids |
| CN103989662A (en) * | 2014-06-09 | 2014-08-20 | 鑫稳药泰医药科技(上海)有限公司 | Formula composition and preparation system of enalapril (Enalapril) cutaneous penetration preparations |
-
2017
- 2017-12-19 CN CN201711372090.7A patent/CN107929268A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005097083A2 (en) * | 2004-03-30 | 2005-10-20 | Dermatrends,Inc. | Transdermal administration of proton pump inhibitors |
| EP2214643B1 (en) * | 2007-11-02 | 2014-04-02 | Acrux DDS Pty Ltd | Transdermal delivery system for hormones and steroids |
| CN103989662A (en) * | 2014-06-09 | 2014-08-20 | 鑫稳药泰医药科技(上海)有限公司 | Formula composition and preparation system of enalapril (Enalapril) cutaneous penetration preparations |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024037545A1 (en) * | 2022-08-17 | 2024-02-22 | 宜昌人福药业有限责任公司 | Dexmedetomidine transdermal composition, transdermal patch, and method for preparing transdermal patch and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6417227B1 (en) | Methods of delivery of cetyl myristoleate | |
| KR101601335B1 (en) | Transdermally absorbable preparation | |
| JP5542665B2 (en) | Matrix-type transdermal administration agent and method for producing the same | |
| KR101192969B1 (en) | Transdermal drug delivery system comprising donepezil | |
| US20180326061A1 (en) | Modified transdermal delivery device or patch and method of delivering insulin from said modified transdermal delivery device | |
| CN101312717A (en) | Transdermal therapeutic system | |
| TWI710381B (en) | Percutaneous absorption preparation | |
| CN102413821A (en) | Transdermal preparation | |
| WO2004110445A1 (en) | Phentanyl-containing adhesive patch for application to oral-cavity mucosa | |
| CN105287361A (en) | External preparation containing non-steroid anti-inflammatory drug microemulsion and used for skin | |
| CN102753158A (en) | Transdermally absorbed preparation of anti-dementia drug | |
| JP2009173679A (en) | Transdermal therapeutic system for administration of partial dopamine-d2 agonist | |
| EA010871B1 (en) | Transdermal formulations and methods for the treatment of thrombocythemia | |
| CN107929268A (en) | A kind of transdermal patch of the medicine containing proton pump inhibitor and preparation method thereof | |
| CN103301093B (en) | Testoderm | |
| CN102281879B (en) | Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone | |
| CN103169685B (en) | A kind of butylphenyl phthaleine controlled release preparation and preparation method thereof | |
| CN102000044A (en) | Azasetron transdermal patch and preparation method thereof | |
| CN103945832B (en) | For brain kinetomeres sustained release and the compositionss of sustained release, device and method | |
| CN104415024B (en) | Cataplasm containing Diclofenac, and combinations thereof and preparation method | |
| CN106692111A (en) | External skin patch containing ketoprofen and preparation method of external skin patch | |
| CN106361728B (en) | Percutaneous absorption preparation and method for producing percutaneous absorption preparation | |
| KR101353478B1 (en) | Transdermal patch for administering fentanyl | |
| JP2012235899A (en) | Microneedle array chip for delivering large amount of target substance into skin | |
| JP4237293B2 (en) | Transdermal patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180420 |
|
| RJ01 | Rejection of invention patent application after publication |